Is Sanofi (SNY) A Good Stock To Buy Now?
Key takeaways
- Ricardo Pillai Fri, June 19, 2026 at 9:56 PM GMT+7 3 min read SNY REGN Is SNY a good stock to buy?
- Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
- Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Is Sanofi (SNY) A Good Stock To Buy Now? Ricardo Pillai Fri, June 19, 2026 at 9:56 PM GMT+7 3 min read SNY REGN Is SNY a good stock to buy? We came across a bullish thesis on Sanofi on r/Value Investing by stefanliemawan. In this article, we will summarize the bulls’ thesis on SNY. Sanofi s share was trading at $42.38 as of June 18th. SNY’s trailing and forward P/E were 18.43 and 8.44 respectively according to Yahoo Finance.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. SNY is presented as a compelling combination of a defensive pharmaceutical company and a potential turnaround opportunity, with the market continuing to discount the business despite its strong portfolio, growing dividend, and ownership of one of the world’s most successful drugs. The company generated €47 billion in revenue last year, including approximately €19 billion from Dupixent, the blockbuster therapy it co-developed with Regeneron.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich